The Oncology Institute to Present at Upcoming ASCO Annual Meeting on High-Value Cancer Care Model Outcomes Showing Cost Savings and Lower Hospitalization Rates
The Oncology Institute (NASDAQ: TOI) has been selected to present significant findings at the upcoming ASCO Annual Meeting regarding their High-Value Cancer Care (HVCC) model. The study demonstrates remarkable improvements in patient care and cost efficiency:
Key outcomes include:
- 53% reduction in Emergency Department use
- 68% decrease in hospitalizations
- 75% lower odds of acute care facility death
- $12,000 cost savings per enrolled patient
According to TOI's Chief Medical Officer, Dr. Yale Podnos, these results validate their coordinated care approach in delivering superior clinical outcomes while significantly reducing costs for patients and payor partners.
L'Istituto di Oncologia (NASDAQ: TOI) è stato selezionato per presentare risultati significativi al prossimo ASCO Annual Meeting riguardo al loro modello di Cure Oncologiche ad Alto Valore (HVCC). Lo studio evidenzia miglioramenti notevoli nella qualità dell'assistenza ai pazienti e nell'efficienza dei costi:
Risultati chiave includono:
- Riduzione del 53% nell'uso del Pronto Soccorso
- Diminuzione del 68% dei ricoveri ospedalieri
- Probabilità inferiore del 75% di decesso in strutture di assistenza acuta
- Risparmio di 12.000$ per ogni paziente iscritto
Secondo il Direttore Medico di TOI, il Dr. Yale Podnos, questi risultati confermano l'efficacia del loro approccio di cura coordinata nel garantire risultati clinici superiori, riducendo significativamente i costi per pazienti e partner pagatori.
El Instituto de Oncología (NASDAQ: TOI) ha sido seleccionado para presentar hallazgos significativos en la próxima Reunión Anual de ASCO sobre su modelo de Atención Oncológica de Alto Valor (HVCC). El estudio demuestra mejoras notables en la atención al paciente y la eficiencia de costos:
Resultados clave incluyen:
- Reducción del 53% en el uso del Departamento de Emergencias
- Disminución del 68% en hospitalizaciones
- 75% menos probabilidades de muerte en instalaciones de atención aguda
- Ahorro de $12,000 por paciente inscrito
Según el Director Médico de TOI, el Dr. Yale Podnos, estos resultados validan su enfoque de atención coordinada para ofrecer resultados clínicos superiores mientras reducen significativamente los costos para pacientes y socios pagadores.
종양학 연구소(NASDAQ: TOI)가 다가오는 ASCO 연례 회의에서 고가치 암 치료(HVCC) 모델에 관한 중요한 연구 결과를 발표하도록 선정되었습니다. 이 연구는 환자 치료와 비용 효율성에서 놀라운 개선을 보여줍니다:
주요 결과는 다음과 같습니다:
- 응급실 이용 53% 감소
- 입원율 68% 감소
- 급성 치료 시설 내 사망 확률 75% 감소
- 등록 환자당 12,000달러 비용 절감
TOI의 최고 의료 책임자 Yale Podnos 박사에 따르면, 이 결과는 환자와 지불 파트너를 위한 비용을 크게 줄이면서 우수한 임상 결과를 제공하는 그들의 통합 치료 접근법을 입증합니다.
L'Institut d'Oncologie (NASDAQ : TOI) a été sélectionné pour présenter des résultats significatifs lors de la prochaine réunion annuelle de l'ASCO concernant leur modèle de soins oncologiques à haute valeur (HVCC). L'étude démontre des améliorations remarquables dans la prise en charge des patients et l'efficacité des coûts :
Les résultats clés incluent :
- Réduction de 53 % de l'utilisation des urgences
- Baisse de 68 % des hospitalisations
- Probabilité réduite de 75 % de décès en établissement de soins aigus
- Économies de 12 000 $ par patient inscrit
Selon le directeur médical de TOI, le Dr Yale Podnos, ces résultats valident leur approche de soins coordonnés, offrant des résultats cliniques supérieurs tout en réduisant considérablement les coûts pour les patients et les partenaires payeurs.
Das Onkologie-Institut (NASDAQ: TOI) wurde ausgewählt, um auf der bevorstehenden ASCO-Jahrestagung bedeutende Ergebnisse zu ihrem High-Value Cancer Care (HVCC)-Modell vorzustellen. Die Studie zeigt bemerkenswerte Verbesserungen in der Patientenversorgung und Kosteneffizienz:
Wichtige Ergebnisse umfassen:
- 53 % Reduktion der Nutzung der Notaufnahme
- 68 % Verringerung der Krankenhausaufenthalte
- 75 % geringere Wahrscheinlichkeit eines Todes in Akutpflegeeinrichtungen
- Kosteneinsparungen von 12.000 $ pro eingeschriebenem Patienten
Dem Chief Medical Officer von TOI, Dr. Yale Podnos, zufolge bestätigen diese Ergebnisse ihren koordinierten Versorgungsansatz, der überlegene klinische Ergebnisse liefert und gleichzeitig die Kosten für Patienten und Kostenträger deutlich senkt.
- Significant 53% reduction in Emergency Department utilization
- Substantial 68% decrease in hospitalization rates
- 75% lower odds of acute care facility death, indicating improved patient outcomes
- Cost savings of $12,000 per enrolled patient
- None.
CERRITOS, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI)(“TOI”), one of the largest value-based oncology groups in the United States, announced today that it has been selected to present an abstract at the upcoming ASCO Annual Meeting further validating cost savings and reduced hospitalizations associated with its unique High-Value Cancer Care (HVCC) model*. The study shares new data supporting prior publications which demonstrate superior outcomes for acute-care patients when enrolled in the TOI HVCC model.
“Without compromising on the clinical outcomes for our oncology patients, TOI has again demonstrated the ability to drive down both Emergency Department utilization and hospitalizations by over
Summary of Outcomes of the Most Recent Clinical Trial Analysis:
53% Lower Emergency Department Use68% Lower Hospitalizations75% Lower Odds of Acute Care Facility Death- Lower Total Cost of Care by
$12,000 per Enrolled Patient
*Patel, et al. Improving care of older adults with cancer: A randomized trial. ASCO Annual Meeting Health Services Section, May 30, 2025.
About The Oncology Institute
Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of over 1.8 million patients including clinical trials, transfusions, and other services traditionally associated with the most advanced care delivery organizations. With over 120 employed clinicians and more than 700 teammates in over 70 clinic locations, TOI is changing oncology for the better.
For more information, visit www.theoncologyinstitute.com
Contacts
Media
The Oncology Institute, Inc.
marketing@theoncologyinstitute.com
Investors
Solebury Strategic Communications
investors@theoncologyinstitute.com
FAQ
What are the key findings of TOI's High-Value Cancer Care model study presented at ASCO 2025?
How much cost savings does The Oncology Institute's (TOI) HVCC model generate per patient?
What is the impact of TOI's care model on hospitalization rates?
How does The Oncology Institute's model affect emergency department utilization?
What is the reduction in acute care facility death rates under TOI's care model?
